CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Business Acquisition, Pro Forma Revenue
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Business Acquisition, Pro Forma Revenue of $1.32 billion for the 12-month period ending 2014-12-27, per its 10-K filed 2015-02-17.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2015-02-17
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma revenue for the quarter ending 2014-12-27 was $329.55M, a 4.97% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma revenue for the quarter ending 2014-09-27 was $327.57M, a 4.50% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma revenue for the quarter ending 2014-06-28 was $341.18M, a 9.32% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma revenue for the quarter ending 2014-03-29 was $324.48M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma revenue for fiscal 2014 was $1.32B, a 5.85% increase from fiscal 2013.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma revenue for fiscal 2013 was $1.25B, a 2.83% increase from fiscal 2012.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma revenue for fiscal 2012 was $1.22B.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2014-12-27 | $329.55M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $657.12M derived: sum of 2 quarters · filed 2015-02-17 | $998.29M derived: sum of 3 quarters · filed 2015-02-17 | $1.32B 10-K · filed 2015-02-17 |
| 2014-09-27 | $327.57M 10-Q · filed 2014-10-30 | $668.75M derived: sum of 2 quarters · filed 2014-10-30 | $993.22M 10-Q · filed 2014-10-30 | $1.31B derived: sum of 4 quarters · filed 2015-02-17 |
| 2014-06-28 | $341.18M 10-Q · filed 2014-08-07 | $665.66M 10-Q · filed 2014-08-07 | $979.61M derived: sum of 3 quarters · filed 2015-02-17 | $1.29B derived: sum of 4 quarters · filed 2015-02-17 |
| 2014-03-29 | $324.48M derived: 10-K 12 month − 3 quarters · filed 2015-02-17 | $638.43M derived: sum of 2 quarters · filed 2015-02-17 | $951.89M derived: sum of 3 quarters · filed 2015-02-17 | $1.26B derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-12-28 | $313.96M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $627.42M derived: sum of 2 quarters · filed 2015-02-17 | $939.51M derived: sum of 3 quarters · filed 2015-02-17 | $1.25B 10-K · filed 2015-02-17 |
| 2013-09-28 | $313.46M 10-Q · filed 2014-10-30 | $625.56M derived: sum of 2 quarters · filed 2014-10-30 | $935.69M 10-Q · filed 2014-10-30 | |
| 2013-06-29 | $312.10M 10-Q · filed 2014-08-07 | $622.23M 10-Q · filed 2014-08-07 | ||
| 2012-12-29 | $1.22B 10-K · filed 2015-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |